1 Antimalarial Drug Resistance Profiling of *Plasmodium falciparum* Infections

2

in India Using Next-Generation Sequencing

3

Sonal Kale^{1,2}*, Swapna M. Uplekar³*, Nabamita Bandyopadhyay¹*, Pavitra N. Rao³*, Syed Z. Ali⁴, S.K. Sharma⁴, Nikunj Tandel⁵, Ankita Patel⁵, Ranvir Singh⁵, Aaron Dank⁵, Sangamithra Ravishankaran⁶, G Sri Lakshmi Priya⁶, Aswin Asokan⁶, Alex Eapen⁶, Om. P. Singh¹, Jane M. Carlton^{3**}, Prashant K. Mallick¹

9

¹National Institute of Malaria Research, Indian Council of Medical Research, Sector 8, Dwarka,

- 11 New Delhi, India
- 12 ² Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and
- 13 Infectious Disease, NIH, Bethesda, Maryland, USA

³Center for Genomics and Systems Biology, Department of Biology, New York University, New

- 15 York, NY, USA
- ⁴ National Institute of Malaria Research Field Unit, Sector 1 Health Center, Rourkela, Odisha,
- 17 India
- ⁵ National Institute of Malaria Research Field Unit, Civil Hospital, Nadiad, Gujarat, India
- ⁶National Institute of Malaria Research Field Unit, Indian Council of Medical Research,
- 20 National Institute of Epidemiology Campus, Ayapakkam, Chennai, Tamil Nadu, India
- 21
- 22 *Authors contributed equally

^{**}Correspondence: J. M. Carlton, New York University, New York, NY 10003
 (jane.carlton@nyu.edu)

- 25 26
- 20
- 27
- 28

30 Abstract

31

Background: Tracking the emergence and spread of antimalarial drug resistance has become
 critical to sustaining progress towards the control and eventual elimination of malaria in South
 Asia, especially India.

35 **Methods:** An amplicon sequencing protocol was used for high-throughput molecular 36 surveillance of antimalarial drug resistance in a total of 158 isolates at three sites in India: 37 Chennai, Nadiad and Rourkela. Five genes of the *Plasmodium falciparum* implicated in 38 antimalarial resistance were investigated here; *Pfcrt* for chloroquine resistance, *Pfdhfr* for 39 pyrimethamine resistance, *Pfdhps* for sulfadoxine resistance, *Pfk13* for artemisinin resistance and 40 *Pfmdr1* for resistance to multiple antimalarials.

41 **Results:** Mutations in the propeller domain of PfK13 were observed in two samples only, 42 however these mutations are not validated for artemisinin resistance. A high proportion of 43 parasites from the *P. falciparum* dominant site Rourkela showed wild-type *Pfcrt* and *Pfdhfr* 44 haplotypes, while mutant *Pfcrt* and *Pfdhfr* haplotypes were fixed at the *P. vivax* dominant sites 45 Chennai and Nadiad. The wild-type PfDHPS haplotype was predominant across all study sites. 46 Finally, we observed the largest proportion of suspected multi-clonal infections at Rourkela, 47 which has the highest transmission of *P. falciparum* among our study sites.

48

49 Conclusion: This is the first simultaneous high-throughput next generation sequencing of five
50 complete *P. falciparum* genes from infected patients in India.

51

52 Keywords: India, *Plasmodium falciparum*, antimalarial drug resistance, deep sequencing,
 53 genomic
 54

- 55
- 56

57 Background

58

59 Malaria remains a major cause of mortality and morbidity in tropical and sub-tropical countries. In 2015, Africa had the greatest malaria burden with 88% of global malaria cases, followed by 60 61 Southeast Asia with 10%, and the eastern Mediterranean region with 2%[1]. India reported 1.2 62 million microscopy-confirmed cases of malaria and 384 deaths due to malaria in 2015, accounting for approximately 89% of malaria cases in South East Asia and 6% of the total 63 64 malaria cases in the world [2]. Over 60% cases in India are caused by *Plasmodium falciparum*. Massive efforts by a worldwide malaria elimination program have reduced the number of 65 66 malaria cases from 2010 by 12% to 214 million in year 2015, and reduced the number of malaria deaths by 21% [3]. India has also joined malaria elimination efforts, allocating financial 67 resources and infrastructure for the launch of a 'National Framework for Malaria Elimination in 68 69 India 2016-2030' [1, 4]. This effort includes all Indian states with varying levels of malaria 70 transmission and outlines specific strategies to achieve the following milestones: 1) eliminate 71 malaria throughout the entire country by 2030; and 2) maintain a malaria-free status in areas 72 where transmission has been interrupted and prevent re-introduction of malaria.

73

The emergence and spread of parasite resistance against available antimalarials constitutes a major threat towards the efforts of the elimination program, as evidenced by the reversal of previous malaria eradication successes to failure [5]. Routine molecular surveillance of parasite strains is an essential tool for identifying and limiting the spread of emerging antimalarial resistance. Sanger sequencing is the gold standard for validation of genotypes identified in parasite clinical isolates, but sensitivity and scalability remain limiting factors; these may be overcome by high-throughput next generation sequencing (NGS) that facilitates the generation of

81 massive amounts of genomic data in a relatively short time by parallelization of sequencing 82 reactions. The technology provides high sequencing coverage, which enables the detection of 83 low-frequency mutations relevant to drug resistance, or low frequency wild-type parasites arising 84 after reversion of mutant genotypes following antimalarial withdrawal from a region. NGS can 85 also provide deep insight into genetic diversity of heterogeneous parasite populations.

86

87 We have previously described a novel amplicon sequencing protocol for high throughput molecular surveillance of drug resistance in field settings [6]. This protocol identifies 88 89 polymorphisms in five important genes implicated in P. falciparum resistance against the mainstay antimalarials; Pfcrt for chloroquine resistance, Pfdhfr for pyrimethamine resistance, 90 91 Pfdhps for sulfadoxine resistance, Pfk13 for artemisinin resistance and Pfmdr1 for resistance to 92 multiple antimalarials. The Center for the Study of Complex Malaria in India (CSCMI) was 93 established in 2010, with the aim of elucidating the epidemiology and transmission of malaria in 94 India at three ecologically diverse sites - Chennai, Nadiad and Rourkela [7]. In this study, we 95 have implemented the aforementioned amplicon-sequencing protocol in field settings to 96 elucidate genomic landscapes of drug resistance at these three CSCMI study sites representing varying transmission ecologies. To our knowledge, this is the first study providing status of 97 98 multiple drug resistance genotypes at these sites.

99

100 METHODS

101 102

104

103 Malaria epidemiology of study sites

105 Chennai, located on the eastern coast of India is the capital city of Tamil Nadu state, and had106 over 7 million inhabitants in 2011. Chennai accounts for 55.6% of all malaria cases in Tamil

107 Nadu, which had an annual parasite index (API) of 0.12 in 2014 [4, 8]. Malaria is hypo-endemic 108 in Chennai, and P. vivax is the dominant species. Subjects were enrolled at the Besant Nagar 109 Malaria Clinic, or in cross-sectional surveys conducted in the Besant Nagar catchment area. 110 Nadiad, located in the Kheda district in Gujarat state (API in 2014: 0.66), had a population of 0.2 111 million in 2011. Nadiad is hypo-endemic for malaria, with slightly higher prevalence of *P. vivax* 112 than P. falciparum. Subjects were enrolled at either the NIMR malaria clinic in Nadiad Civil 113 Hospital or at an urban health center in the Vatva ward of Ahmedabad city, the capital of Gujarat 114 state. Alternately, subjects were enrolled in cross-sectional surveys conducted in the vicinity of 115 Nadiad town. Rourkela, located in Sundargarh district close to the northern border of the state of 116 Odisha (API in 2014: 9.08), had a population of over 0.5 million in 2011. Rourkela has meso-to-117 hyperendemic transmission of malaria, with P. falciparum as the dominant species. Subjects 118 were enrolled at a health center clinic set up in a suburb of Rourkela, and in cross-sectional 119 surveys conducted in rural areas around Rourkela.

120

122

121 Sample collection and processing

158 of 300 P. falciparum isolates collected as part of the CSCMi study [7] and tested using our 123 124 amplicon sequencing protocol [6] were sequenced successfully, with amplification failing in 125 isolates with poor quality or low concentration of DNA. These isolates were collected from 141 126 study enrollees at three sites: Chennai (18 isolates from 15 patients), Nadiad (55 isolates from 41 127 patients) and Rourkela (85 isolates from 85 patients), between December 2012 and September 128 2015 (Table 1). A majority of the enrollees were male (98 male, 43 female). Patients were 129 between 2-69 years old, with a mean age of 27.44 (95%CI: 24.83-30.07). Asexual or sexual P. 130 *falciparum* parasitemia was detectable by microscopy in 140 isolates, with a mean parasitemia of 131 14073.16 parasites/ul (95%CI: 3822.15- 24324.18); 18 isolates were submicroscopic. 149

isolates were positive for *Plasmodium falciparum* species-specific PCR, 9 were PCR negative.
Patients were enrolled after obtaining informed consent, and treated with antimalarials as per the
Indian national guidelines [9].

135

137

136 DNA extraction, library preparation and sequencing

138 DNA was extracted from P. falciparum-infected blood samples collected on Whatman filter 139 paper, small EDTA microvettes or EDTA vacutainers using QIAamp DNA Blood Mini or Midi 140 Kit (Qiagen Inc., catalog nos. 51106, 51185) after separation of plasma, and 1-5 ul was used as a 141 template for amplicon synthesis. Primers and PCR conditions were as outlined in [6]. For each 142 sample, 10 ul of every amplicon was pooled, and the pooled mixture was purified using the 143 QIAquick PCR Purification Kit (Qiagen Inc., catalog no. 28106) and quantitated using a Qubit 144 2.0 fluorometer (Thermo Fisher Scientific, catalog no. Q32866). Barcoded sequencing libraries were generated from 100-500 ng of purified pooled PCR product using ion expressTM barcode 145 adapters (Life Technologies, catalog no. 4471250 for barcodes 1-16; catalog no. 4474009 for 146 147 barcodes 17-32) and library prep kit (New England Biolabs, catalog no. E6285L). The size and 148 quality of libraries were determined using an Agilent bioanalyzer, and quantified by quantitative 149 PCR using Ion Torrent Library Quantification kit (KK4857, KAPA biosystems) on a LightCycler^R 480 (Roche). For most experiments, 16 barcoded libraries were pooled for a single 150 run on the PGM using Ion PGMTM Hi-OTM sequencing technology and IonTM 314v2 type chips, 151 except for one library pool that was run on an IonTM 318v2 chip. Genomic DNA from P. 152 153 falciparum strains Dd2 (MRA-150G) and 7G8 (MRA-152G) was obtained from the Malaria 154 Research and Reference Reagents Resource (MR4). Control libraries prepared with Dd2 or 7G8 155 DNA were included in each run. We also sequenced ten additional P. falciparum reference 156 strains (NF54 E, TM91C235, HB3, W2, K1, V1/S, D10, GB4, D6, FCB) as part of different runs

to ensure that our variant calling results showed complete concordance with previously publisheddata for these isolates.

159

161

160 Data processing

Sequencing data were analyzed using the Ion Torrent platform software (Torrent Suite 5.0.2). Raw reads were de-multiplexed and filtered using standard quality filtering parameters by Torrent Suite pipeline software. Read quality was assessed using the Torrent Suite FastQC plugin v0.10.1, and high-quality reads were aligned to the reference using the Torrent Mapping Alignment Program v5.0. The reference data file used was a multi-FASTA file containing the complete gene sequence and 300bp flanking regions for each amplicon target gene from the P. falciparum 3D7 genome using the PlasmoDB database .

169

170 Data analysis

171

172 Variant calling was performed with low stringency parameters using the Ion Torrent Variant 173 Caller plugin (v5.0). We generated a list of all positions in all genes that were variable in at least 174 one sample; for samples where no variants were reported at these positions, the presence of the 175 reference allele was confirmed by obtaining raw nucleotide counts and quality scores from 176 corresponding BAM files using BEDTools. Variant filtering criteria was determined based on 177 the quality of known SNPs in MR4 reference isolates sequenced in each run. Variant calls with 178 SNP allele depth < 10 reads and base quality score < 10 were discarded. Calls with SNP allele 179 frequency between 20% - 80% were marked as heterozygous and subsequently used to classify 180 samples as multi-clonal infections, i.e. containing more than one distinct parasite genotype. SNP 181 calls were processed to determine codon changes based on the P. falciparum 3D7 gene 182 annotation from the PlasmoDB database using custom Perl and MS Excel VBA scripts. In the

183 case of multiple nucleotide polymorphisms (MNPs) affecting the same codon, if both SNP 184 alleles occur at a frequency > 80%, they were merged to calculate the resulting codon change; 185 variant calls with SNP allele frequency < 20% were discarded. For the *Pfcrt* gene, MNPs 186 affecting codon positions 72-76 were filtered using a higher SNP allele frequency cut-off of 187 30%. A high proportion of homo-polymer repeats in the *Pfcrt* gene led to poor sequencing 188 quality misalignment of reads. As a result variants in this gene were manually curated using the 189 IGV genome browser, particularly for the genomic locus corresponding to codons 72-76. 190 Population structure was examined using a non-model-based multivariate analysis method as 191 implemented in the adegenet 2.0.1 package using the *dudi.pca* function. In the case of multi-192 allelic SNPs, the major allele call was used to represent the dominant genotype at that position.

193

195

194 **RESULTS**

196 We have successfully sequenced a panel of five *P. falciparum* genes implicated in antimalarial 197 drug resistance in clinical isolates from India using a previous validated amplicon sequencing 198 protocol [6]. Pfk13, Pfcrt, Pfmdr1, Pfdhfr and Pfdhps have been implicated in resistance to first-199 line antimalarial therapy, including artemisinin combination therapy, chloroquine, and sulfadoxine-pyrimethamine. We deduced SNP haplotypes from key resistance-associated alleles 200 201 in the target genes for 158 isolates collected at three sites in India. Implications of the resistance 202 mutations identified at the three sites have been described below in the context of each drug they 203 are associated with.

204

206

205 **Resistance to chloroquine**

207 Mutations encoding amino acid substitutions in the chloroquine resistance transporter PfCRT 208 (PF3D7_0709000) at positions 72, 74, 75, 76, 97, 220, 271, 326, 356 and 371 have been

209 associated with increased resistance to chloroquine (CO), with the K76T substitution being the 210 primary mediator of resistance [10-12]. 147 of 158 isolates sequenced carried only one haplotype 211 at the PfCRT locus; one isolate had multiple PfCRT haplotypes, and 10 isolates had partial or missing PfCRT haplotype data (Table 2). The CQ-resistant PfCRT haplotype $S^{72}V^{73}M^{74}N^{75}T^{76}$, 212 213 purported to be the most prevalent PfCRT haplotype in India [13], was present in 71/147 isolates, including all isolates from Chennai and most isolates from Nadiad, but only two isolates 214 from Rourkela. Contrastingly, the CQ-sensitive wild-type haplotype $C^{72}V^{73}M^{74}N^{75}K^{76}$ was 215 216 detected in 46 isolates from Rourkela, but absent from Nadiad and Chennai. The CQ-resistant haplotype C⁷²V⁷³I⁷⁴E⁷⁵T⁷⁶ was present in 30/147 isolates: 28 isolates from Rourkela and 2 217 218 isolates from Nadiad. Both copy number variation and mutations encoding substitutions in the 219 multidrug resistance protein PfMDR1 (PF3D7_0523000) codons 86, 184, 1034, 1042 and 1246 220 can modulate resistance to various antimalarial drugs (summarized in [14]). While our protocol 221 does not permit gene copy number assessment, we were able to identify polymorphisms 222 associated with resistance to CQ. 129 of 158 isolates sequenced carried only one PfMDR1 223 haplotype, while 10 isolates possessed more than one PfMDR1 haplotype, which may be 224 attributed to increased *Pfmdr1* copy number (Table 2). 19 isolates had partial or missing haplotype data. The single-mutant PfMDR1 haplotype N⁸⁶F¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ was predominant 225 226 (57/129)study, and the wild-type PfMDR1 haplotype among isolates in our N⁸⁶Y¹⁸⁴S¹⁰³⁴N¹⁰⁴²D¹²⁴⁶ was also prevalent in several (45/129) isolates. Double-mutant PfMDR1 227 haplotypes were rare, with only 5/129 isolates containing the haplotypes $Y^{86}F^{184}S^{1034}N^{1042}D^{1246}$ 228 or $N^{86}F^{184}S^{1034}D^{1042}D^{1246}$. The single mutation-bearing haplotype $Y^{86}Y^{184}S^{1034}N^{1042}D^{1246}$ was 229 230 present in 22/129 isolates, 11 each from Nadiad and Rourkela.

231 A total of 12 haplotype combinations between the PfCRT and PfMDR1 loci were seen in 232 122 isolates with complete sequence information for these genes across the three sites. Rourkela 233 had the largest diversity of haplotypes, with 10 haplotype combinations at these two loci, and 234 Chennai had the least diversity (Table 3), with only one haplotype combination. The PfCRT and PfMDR1 haplotype combination of $S^{72}V^{73}M^{74}N^{75}T^{76} + N^{86}F^{184}S^{1034}N^{1042}D^{1246}$ was most common 235 236 among isolates surveyed in our study (47/122), but was seen primarily in Chennai and Nadiad and not in Rourkela. The combination of wild-type haplotypes at both loci ($C^{72}V^{73}M^{74}N^{75}K^{76}$ + 237 $N^{86}Y^{184}S^{1034}N^{1042}D^{1246}$) was seen only at Rourkela, and present in the highest proportion at that 238 239 site.

240

242

241 **Resistance to sulfadoxine-pyrimethamine**

243 Mutations encoding amino acid substitutions at positions 51, 59, 108, 164 in the enzyme 244 dihydrofolate reductase PfDHFR (PF3D7 0417200) are associated with increased resistance to 245 pyrimethamine (PYR), with the S108N mutation primarily responsible for resistance [15, 16]. 137 of 158 isolates sequenced carried only a single haplotype at the PfDHFR locus; 12 isolates 246 247 carried multiple PfDHFR haplotypes and 9 isolates had partial or missing PfDHPS haplotype data (**Table 2**). The double-mutant PfDHFR haplotype $A^{16}N^{51}R^{59}N^{108}I^{164}$ was most common 248 among isolates (99/137) in our study, while the single-mutant A¹⁶N⁵¹C⁵⁹ N¹⁰⁸I¹⁶⁴ haplotype was 249 extremely rare (1/137): triple $(A^{16}I^{51}R^{59}N^{108}I^{164})$ or quadruple $(A^{16}I^{51}R^{59}N^{108}L^{164})$ mutant 250 251 haplotypes could not be detected. Several isolates (37/137) had only the PYR-sensitive wild-type PfDHFR haplotype A¹⁶N⁵¹C⁵⁹S¹⁰⁸I¹⁶⁴. Resistance to sulfadoxine (SUL) has been associated with 252 253 mutations encoding amino acid substitutions at positions 436, 437, 540, 581 and 613 in the 254 enzyme dihydropteroate synthetase (PfDHPS), with the A437G substitution arising first [17, 18].

143 of 158 isolates sequenced carried only a single haplotype at the PfDHPS locus; 15 isolates had partial or missing PfDHPS haplotype data. The SUL-sensitive wild-type PfDHPS haplotype $S^{436}A^{437}K^{540}A^{581}A^{613}$ predominated in our study, with 134/143 isolates carrying only this haplotype. Two isolates from Rourkela possessed the triple mutant PfDHPS haplotype $A^{436}G^{437}E^{540}A^{581}A^{613}$, while the double mutant haplotype $S^{436}G^{437}E^{540}A^{581}A^{613}$ was only detected in a single isolate. Six isolates carried the single-mutant $S^{436}G^{437}K^{540}A^{581}A^{613}$ haplotype.

261 A total of 5 haplotype combinations between the PfDHFR and PfDHPS loci were seen in 129 isolates with complete sequence information for these two genes across the three sites 262 (Table 3). The combination of double-mutant PfDHFR with wild-type PfDHPS 263 $(A^{16}N^{51}R^{59}N^{108}I^{164} + S^{436}A^{437}K^{540}A^{581}A^{613})$ was predominant among isolates in our study 264 265 (87/129). Two samples from Rourkela had the strongest predictors of treatment failure in our of double-mutant PfDHFR with triple-mutant PfDHPS 266 datasetthe combination $(A^{16}N^{51}R^{59}N^{108}I^{164} + A^{436}G^{437}E^{540}A^{581}A^{613})$. Only 33 isolates, primarily from Rourkela, carried 267 268 wild-type haplotypes at both loci. Two other haplotype combinations were observed in the population: $(A^{16}N^{51}R^{59}N^{108}I^{164} + S^{436}G^{437}K^{540}A^{581}A^{613})$. seen in six 269 isolates and $(A^{16}N^{51}C^{59}N^{108}I^{164} + S^{436}G^{437}E^{540}A^{581}A^{613})$ seen in one isolate. 270

271

272 Resistance to artemisinin combination therapies

273

274 Mutations in the propeller domain of the kelch protein PfK13 (PF3D7_1343700) have been 275 shown to be associated with resistance to artemisinin derivatives [19, 20], which is defined as a 276 delayed clearance of parasites from the blood following artemisinin administration [21]. The 277 Pfk13 gene was completely conserved among 92/158 isolates that were successfully sequenced at 278 this locus, and a majority of the SNPs observed in the remaining isolates led to synonymous

changes (60/92 SNPs). Only 2 isolates had substitutions in the propeller domain: V555L in
N0319-V1, and A578S in R5025. We did not identify any of the four validated SNPs (C580Y,
R539T, I543T or Y493H) implicated in artemisinin resistance in our isolates [19, 22]. The
K189T mutation was seen in 17 isolates in our study, all from Rourkela. Mutations encoding
amino acid substitutions in PfCRT, (such as I356T) are part of the genetic background associated
with the emergence of artemisinin resistance [23], and were present in 20 isolates from our study
(18 from Rourkela, 2 from Nadiad).

Resistance to the artemisinin combination therapy (ACT) partner drugs lumefantrine, mefloquine and piperaquine, has also been linked to certain PfCRT and PfMDR1 haplotypes. The wild type PfCRT K76 allele, associated with lumefantrine tolerance [24], was present in 46/129 isolates, all from Rourkela. The wild-type N86 allele of PfMDR1, associated with decreased susceptibility to lumefantrine [25], was observed in 103 of a total of 129 isolates in our study bearing only one PfMDR1 haplotype. The N⁸⁶F¹⁸⁴D¹²⁴⁶ haplotype, selected for after artemetherlumefantrine (AL) treatment in Africa [26, 27], was observed in 58/129 isolates.

293

294 295

Analysis of longitudinal Plasmodium samples from an individual

For a few enrollees (14/141), drug resistance genes were sequenced from parasite isolates collected on day 2, day 7 or day 14 following ACT treatment. Of these, three individuals were from Chennai and eleven from Nadiad. A majority of the post-treatment follow-up samples had drug resistance haplotypes that were identical to samples collected from the same patient on enrollment (**Supplementary Table 2**). However, enrollee N0319 had a mixture of wild-type $(N^{86}Y^{184}S^{1034}N^{1042}D^{1246})$ and mutant $(Y^{86}F^{184}S^{1034}N^{1042}D^{1246})$ PfMDR1 haplotypes on the day of enrollment, but on day 2, only the mutant $(Y^{86}F^{184}S^{1034}N^{1042}D^{1246})$ haplotype could be detected

303 (Supplementary Table 2). Most enrollees in our study did not have parasitemia detectable by
304 microscopy or PCR on day 2 following ACT treatment.

- 305
- 306 307

06 Using heterozygous variants for COI estimation

In order to identify possible multi-clonal infections among the clinical isolates, we ranked the isolates based on the total number of high-quality heterozygous variants (i.e. positions containing more than one allele), similar to [6] (**Figure 1**). Isolates containing more than twice the median number of heterozygous variants in the dataset were classified as potential multi-clonal infections. This included 30 isolates in total, 8 from Nadiad and 22 from Rourkela (**Supplementary Table 3**). We did not identify any multiclonal infections in Chennai.

314

316

315 Clustering of isolates based on drug resistance haplotypes

317 In order to identify population-specific variation in the drug resistance genes we performed 318 principal component analysis (PCA) using sequence data at 230 polymorphic positions. The first 319 two principal components accounted for 49.1% of the variation in the SNP data (PC1=30.74%, 320 PC2=18.36%). The PCA showed isolates from Chennai and Nadiad clustering together, while 321 isolates from Raurkela were split into two separate clusters (Figure 2a). Further analysis 322 revealed that the three clusters correspond to distinct PfCRT haplotypes (codons 72-76). The two clusters of isolates from Raurkela were associated with haplotypes $C^{72}V^{73}I^{74}E^{75}T^7$ and 323 C⁷²V⁷³M⁷⁴N⁷⁵K⁷⁶, whereas the cluster containing isolates from Chennai and Nadiad was 324 associated with the $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype. Depending on the specific PfCRT haplotype, 325 326 MR4 reference strains were placed across all three clusters (Figure 2b).

327

328 DISCUSSION

329

Tracking the emergence and spread of antimalarial drug resistance has become critical to sustaining progress towards the control and eventual elimination of malaria in South Asia, especially India. *P. falciparum* has evolved resistance to virtually every drug introduced to combat it, due to several factors such as substandard drug quality, improper prescription practices, and consumption of drugs as mono-therapy instead of combination therapies.

335

336 Chloroquine (CQ) was widely used as an antimalarial across the world since the 1930s, due to its 337 high efficacy and relative inexpensiveness. In the 1950s CQ-resistant P. falciparum arose 338 simultaneously in South America and South East Asia; it was first detected in India by 1973 and eventually spread through the country [28]. CQ remained the first-line therapy for P. vivax 339 340 infections in India, even after its use against P. falciparum was discontinued. Membrane 341 transporters such as PfCRT and PfMDR1 can acquire mutations that may modulate resistance to 342 CQ by reducing accumulation of CQ in the food vacuole [29]. We observed a diverse 343 distribution of three PfCRT and five PfMDR1 haplotypes in isolates across our study sites. The CQ resistance-associated PfCRT S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ haplotype was fixed in the Chennai and 344 Nadiad, while parasites in Rourkela possessed either the CQ resistance-associated PfCRT 345 $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype or the CQ-sensitive, wild-type PfCRT $C^{72}V^{73}M^{74}N^{75}K^{76}$ haplotype. 346 Among the three study sites, Rourkela has the highest prevalence of *P. falciparum*, followed by 347 348 Nadiad and Chennai. Conversely, the prevalence of *P. vivax* is higher in Chennai and Nadiad, leading to higher CQ usage and drug pressure, possibly explaining the expansion of the PfCRT 349 $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype at these two sites. The $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype from PNG [30, 350 351 31] may have been introduced to South India through Sri Lanka or the Andaman and Nicobar 352 Islands and subsequently spread through the rest of the country [32]. It is evident through the

medRxiv preprint doi: https://doi.org/10.1101/2023.04.08.23288321; this version posted April 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

PCA that the parasite population in Rourkela is split into two distinct clusters, corresponding to 353 CO-resistant $(C^{72}V^{73}I^{74}E^{75}T^{76})$ and CO-sensitive $(C^{72}V^{73}M^{74}N^{75}K^{76})$ haplotypes. While the 354 PfCRT $S^{72}V^{73}M^{74}N^{75}T^{76}$ haplotype is predominant in most of India. earlier studies have shown 355 that the eastern state of Orissa has a higher prevalence of the $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype [33, 34]. 356 The C⁷²V⁷³I⁷⁴E⁷⁵T⁷⁶ haplotype may have been introduced to Rourkela through North-East India, 357 following the well-established migratory route of South East Asian P. falciparum strains into 358 359 India. We propose that in the absence of CQ pressure in Rourkela, there is reversion to the wildtype $C^{72}V^{73}M^{74}N^{75}K^{76}$ haplotype from the mutant $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype as the fitness cost 360 associated with the $C^{72}V^{73}I^{74}E^{75}T^{76}$ haplotype may be greater than that of the $S^{72}V^{73}M^{74}N^{75}T^{76}$ 361 362 haplotype [35]. CQ resistance can also be modulated by mutations in PfMDR1 when they occur 363 in the background of resistance-conferring mutations in PfCRT [35]. The PfMDR1 substitution N86Y contributes to CO-resistance but has been associated with sensitization of P. falciparum 364 parasites to dihydroartemisinin (DHA) and lumefantrine (LMF) [36]. We observed a 365 predominance of the PfMDR1 N86 allele and PfCRT S⁷²V⁷³M⁷⁴N⁷⁵T⁷⁶ haplotype in Chennai and 366 Nadiad, which corroborates with previous observations in regions of low P. falciparum 367 368 transmission in India by Mallick et al [37], who also identified a mixture of mutant and wild-369 type haplotypes in high transmission regions.

370

Following widespread CQ resistance, a combination of the antifolates sulfadoxine and pyrimethamine (SP) was introduced as the second-line antimalarial treatment for *P. falciparum* in 1982. Resistance to sulfadoxine (SUL) and pyrimethamine (PYR) has been associated with mutations in the folate biosynthesis pathway enzymes, *Pfdhps* and *Pfdhfr* respectively; it has been proposed that these enzymes reduce binding of the antifolates to their targets. In our study,

medRxiv preprint doi: https://doi.org/10.1101/2023.04.08.23288321; this version posted April 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

the wild-type SUL-sensitive PfDHPS haplotype S⁴³⁶A⁴³⁷K⁵⁴⁰A⁵⁸¹A⁶¹³ was predominant across all 376 377 three sites, occurring primarily in combination with the PYR-resistant, double-mutant PfDHFR haplotype A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ in Nadiad and Chennai. However, at Rourkela, there were 378 comparable numbers of isolates with the wild type $A^{16}N^{51}C^{59}S^{108}I^{164}$ and double-mutant 379 A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ DHFR haplotypes. The double mutant A¹⁶N⁵¹R⁵⁹N¹⁰⁸I¹⁶⁴ PfDHFR haplotype 380 381 was predominant at each site, corroborating with previous studies from India [34, 37]. We 382 primarily detect wild-type PfDHPS and double-mutant PfDHFR haplotypes, that confer no 383 resistance or low-level resistance to PYR and SUL, respectively. This observation coupled with the absence of quadruple or quintuple mutant haplotypes at all three sites suggest that P. 384 385 falciparum resistance to SP therapy at these three sites is very low [37].

386

387 Artemisinin (ART) and its derivatives-artesunate, artemether, dihydroartemisinin are among the 388 most effective antimalarials currently available. Owing to their short half-lives in the blood, they 389 are administered in combination with partner drugs with longer half-lives, such as lumefantrine, 390 piperaquine, etc., in order to kill residual parasites. Artemisinin combination therapy (ACT) was 391 recommended as first-line treatment for P. falciparum infections by the WHO in 2005. In most 392 parts of India artesunate is used in combination with sulfadoxine and pyrimethamine (AS-SP), 393 except for the North-East region where the combination of artemether and lumefantrine (AL) is 394 used instead, due to widespread SP resistance [9]. Artemisinin resistance was first identified in 395 Cambodia and spread quickly through South East Asia, while also emerging simultaneously at 396 different foci in South Asia. Mutations in the propeller domain of the kelch protein K13 were 397 shown to be associated with delayed clearance of parasites after ACT treatment [19, 20]. Since 398 K13 mutations were recently detected in an area of Myanmar that is adjacent to the eastern

399 border of India [38], there has been concern about the spread of artemisinin resistance into India, 400 in a manner similar to the previous spread of CQ and SP resistance. If artemisinin fails, there is no drug with comparable efficacy to replace it. While ACT failure has been reported in North 401 402 East India, it may be attributed to failure of the partner drugs [39, 40], and studies examining the 403 propeller domain have not detected any mutations associated with resistance among Indian 404 isolates except F446I, which remains to be validated [41-43]. Our study identified two mutations 405 in the propeller region – one from an isolate in Nadiad, and the other from Rourkela. The V555L 406 substitution (seen in sample N0319-V1) has been detected in Senegal at a very low frequency 407 [44], while A578S (seen in R5025) has been detected in several isolates from Africa, India and 408 Bangladesh [22, 41, 42, 45]. Neither has been associated with resistance among field isolates or 409 in *in vitro* assays. The K189T mutation that was identified in a subset of the Rourkela population 410 has previously been seen in isolates from Senegal, Guyana, the China-Myanmar border, and 411 Northeast India [42, 46-48]. The wild-type N86 allele of PfMDR1 and the wild-type K76 allele 412 of PfCRT were selected after artemether-lumefantrine combination therapy in Africa [24-27] and 413 were associated with decreased susceptibility to lumefantrine *in vitro* [24]. Our data suggests that 414 AL treatment is likely be effective in areas with a predominance of CQ-resistant PfCRT haplotypes $S^{72}V^{73}M^{74}N^{75}T^{76}$ (Chennai and Nadiad) and $C^{72}V^{73}I^{74}E^{75}T^{76}$ (Rourkela) as well as the 415 PfMDR1 haplotypes $Y^{86}F^{184}S^{1034}N^{1042}D^{1246}$ and $Y^{86}Y^{184}S^{1034}N^{1042}D^{1246}$ (Nadiad and Rourkela). 416

417

418 Parasite isolates from Rourkela showed greater diversity than isolates from Chennai and Nadiad 419 at all drug resistance loci. PCA clustering revealed that parasites from Chennai and Nadiad were 420 more closely related, whereas the parasites in Rourkela separated into two populations that were 421 associated with distinct PfCRT haplotypes. There was a near-equal distribution of wild-type and

422 mutant haplotypes at the Pfcrt, Pfdhfr and Pfmdr1 loci in Rourkela. The eight isolates in our 423 dataset that possessed wild-type haplotypes at all the drug resistance loci were also from 424 Rourkela. Interestingly, over 70% of the potential multi-clonal infections identified were from 425 Rourkela, the remainder from Nadiad, and none were from Chennai. We suspect that as a result 426 of higher prevalence and transmission of P. falciparum in Rourkela, the complexity of infection 427 may be higher at this site, compared to Nadiad or Chennai, where the prevalence of P. 428 falciparum is much lower.

429

430 We have demonstrated the potential of amplicon sequencing to discriminate between single- and 431 multi-clonal infections. Another application of this method is to study the variation in within-432 host diversity in response to chemotherapy. This is particularly interesting for multi-clonal 433 infections as it can enable us to track changes in the frequency of individual alleles before and 434 after drug treatment [49]. Our analysis of parasite isolates from follow-up (collected after ACT-435 treatment) samples was limited to a small number of samples from Chennai and Nadiad. For all 436 pairs of isolates collected from same individual, the key drug resistance SNPs were identical 437 enrollment and follow-up isolates, except in the case of one patient isolate in Nadiad (N0319) 438 that possessed a mixture of CQ-resistant and CQ-sensitive haplotypes at the Pfmdr1 locus at 439 enrollment, but retained only the CQ-resistant haplotype following drug treatment. The potential 440 multi-clonal infections identified in our study did not include any pairs of follow-up isolates, mainly because we did not have any follow-up samples collected in Rourkela. The likelihood of 441 442 the pretreatment infection being multi-clonal is much lower in Chennai and Nadiad, compared to 443 Rourkela because of lower COI. Therefore, it is not surprising that we identified the same 444 parasite haplotypes in patients, pre-and post-ACT administration.

445

446	We have established amplicon sequencing as an important tool for high-throughput molecular
447	surveillance of antimalarial drug resistance in India, especially since it can be implemented in
448	field settings, as we have demonstrated in this study.
449	
450	Abbreviations
451	MSP-1 ₁₉ : merozoite surface protein-1 ₁₉
452	AMA-1: apical membrane antigen-1
453	
454	Declarations
455	Ethics approval and consent to participate
456	Ethical approval to conduct this study was obtained from New York University Institutional
457	Review Board (Study #i10-00173) and the Ethics Committee of the National Institute of Malaria
458	Research, India (ICMR). All project staff completed Protection of Human Research Subjects
459	training prior to beginning the study, and clinical samples were collected after informed consent
460	was obtained from all participants.
461	
462	Author's Contributions

463 JMC, OPS, PKM, designed the study. OPS, JMC, PKM contributed reagents/materials/analysis

tools. AA, SR, SLPG, NT, SZA, HCS, SKS, AE contributed in sample collection and processing.

- 465 SK, NB performed the experiments. SK, SU, PR, PKM analyzed and interpreted data. SK, SU,
- 466 PR wrote the first draft. PKM, OPS, JMC reviewed and edited the manuscript. All authors read
- 467 and approved the final manuscript.

469 Acknowledgments

We thank MR4 for providing malaria parasite strains. We are indebted to Drs. Lalitha Ramanathapuram, Patrick Sutton, Anna Maria van Eijk and all members of the CSCMi teams in Delhi, Nadiad, Raurkela and Chennai for their support. Dr. Martina Bradic's help with the linkage analysis is greatly appreciated. We also thank Dr. Neena Valecha and the staff of the National institute of Malaria Research in Delhi, India for use of the facilities.

Competing interests

476 All authors have declared that no competing interests exist.

477 Financial support

This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI089676 as part of the International Centers for Excellence in Malaria Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Tables

506 Table 1: Sample summary and descriptive statistics

Category	Chennai	Nadiad	Raurkela	Total
Enrollment period	Dec 2012 - Oct 2014	Sep 2013 - Sep 2015	Mar 2013 - Nov 2014	N/A
No. of enrollees	15	41	85	141
Male	10	30	58	98
Female	5	11	27	43
Age range	13-50	13-60	2-69	2-69
Travel in last 14 days	2	7	11	20
No. of isolates	18	55	85	158
Microscopic	16	54	70	140
Submicroscopic	2	1	15	18
Average parasitemia (parasites/ul)	2867.56	9812.8	19202.82	10627.73
Clinic	14	39	21	74
Cross sectional	3	16	61	80
Other studies	1	0	3	4

0 Table 2: Frequency of haplotypes associated with drug resistance at three sites in India

Molecular Marker	Haplotype	Chennai	Nadiad	Raurkela	Predicted phenotype
PfCRT	C V M N K	-	-	0.54	S
	<u>s</u> v m n <u>t</u>	1.00	0.93	0.02	RR
	CVIET	-	0.04	0.33	RRR
	Unresolved	-	0.04	0.10	
PfDHFR	ANCSI	0.11	0.11	0.34	S
	ANC <u>N</u> I	-	-	0.01	R
	AN <u>RN</u> I	0.89	0.82	0.45	RR
	Unresolved	-	0.07	0.20	
PfDHPS	SAKAA	0.89	0.87	0.82	S
	SGKAA	0.11	0.07		R
	S <u>GE</u> AA	-		0.01	RR
	AGEAA	-	-	0.02	RRR
	Unresolved	-	0.05	0.14	
PfMDR1	NYSND	-	0.04	0.51	S
	<u>Y</u> Y S N D	-	0.20	0.13	R
	NESND	0.94	0.53	0.13	R
	N F S <u>D</u> D	-	-	0.01	RR
	YESND		0.07		RR
	Unresolved	0.06	0.17	0.23	-

- 515 Table 3: Frequency of combination haplotypes associated with drug resistance at three sites in
- 516 India
- 517

Molecular Marker	Haplotype	Chennai	Nadiad	Raurkela
PfCRT - PfMDR1	CVMNK-NYSND			0.39
	C V M N K – N <u>F</u> S N D		-	0.11
	$C V M N K - \underline{Y} Y S N D$			0.07
	<u>S</u> VMN <u>T</u> -N <u>Y</u> SND		0.05	-
	<u>S</u> VMN <u>T</u> -N <u>E</u> SND	1.00	0.66	0.02
	<u>S</u> V M N <u>T</u> – <u>Y</u> Y S N D		0.20	0.02
	SVMNT-YESND		0.07	-
	CVIET-NYSND			0.23
	CVIET-NESND			0.05
	C V L E T - N F S D D			0.02
	CVIET-YYSND		0.02	0.10
PfDHFR - PfDHPS	ANCSI-SAKAA	0.11	0.12	0.41
	A N C <u>N</u> I – S <u>G E</u> A A			0.02
	AN <u>RN</u> I-SAKAA	0.78	0.80	0.54
	ANRNI-SGKAA	0.11	0.08	
	ANRNI-AGEAA			0.03

518 519 520

521 Figure Legends

522

523 Figure 1: Estimation of mixed genotypes using heterozygous variant calls.

524 Plot showing number of high quality heterozygous variant calls (y-axis) for each *P. falciparum* 525 clinical isolate. Isolates on the left of the vertical dotted line, which represents twice the median 526 number of heterozygous variants observed in the entire dataset, were classified as potential

527 mixed genotype infections.



528 529

Figure 2: Principal component analysis using high quality SNP data from all *P. falciparum*isolates. (A) Each isolate is colored by site (B) Each isolate is colored by site and shape denotes
haplotype observed at PfCRT 72-76 locus. Unresolved refers to missing or partial data and
mixed infection samples.

534



535 536

537

538 Supplementary Excel File

Supplementary Table 1: List of annotated, high-quality SNPs in six P. falciparum genes reportedby the Ion Torrent PGM Variant Caller Plugin

541 Supplementary Table 2: Data for follow-up patient samples showing key SNPs implicated in
542 drug resistance from six P. falciparum genes (represented as haplotypes).

543 Supplementary Table 3: High-quality SNPs in samples classified as potential multi-clonal 544 infections

545 546

547 **REFERENCES**

- 548
- Wangdi, K., et al., *Malaria elimination in India and regional implications*. Lancet Infect
 Dis, 2016. 16(10): p. e214-24.
- 551 2. WHO, World Malaria Report 2016. 2016.
- 552 3. WHO, World Malaria Report 2015- December 2015. 2015.
- 553 4. NVBDCP, National Framework for Malaria Elimination in India 2016–2030
- 5. Shah, N.K., et al., Antimalarial drug resistance of Plasmodium falciparum in India:
 changes over time and space. Lancet Infect Dis, 2011. 11(1): p. 57-64.
- 556 6. Rao, P.N., et al., A Method for Amplicon Deep Sequencing of Drug Resistance Genes in
 557 Plasmodium falciparum Clinical Isolates from India. J Clin Microbiol, 2016. 54(6): p.
 558 1500-11.
- 559 7. Das, A., et al., *Malaria in India: the center for the study of complex malaria in India.*560 Acta Trop, 2012. **121**(3): p. 267-73.
- 5618.NationalHealthMissionTamilNadu,D.o.H.a.F.W.;Availablefrom:562http://www.nrhmtn.gov.in/vbdc.html.
- 563 9. Anvikar, A.R., et al., Antimalarial drug policy in India: Past, present & future, in Indian
 564 J Med Res. 2014. p. 205-15.
- 565 10. Sidhu, A.B., D. Verdier-Pinard, and D.A. Fidock, *Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations*. Science, 2002. 298(5591): p. 210-3.

- Fidock, D.A., et al., Mutations in the P. falciparum digestive vacuole transmembrane
 protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell, 2000.
 6(4): p. 861-71.
- 571 12. Djimde, A., et al., *Application of a molecular marker for surveillance of chloroquine-*572 *resistant falciparum malaria.* Lancet, 2001. **358**(9285): p. 890-1.
- 573 13. Vathsala, P.G., et al., *Widespread occurrence of the Plasmodium falciparum chloroquine*574 *resistance transporter (Pfcrt) gene haplotype SVMNT in P. falciparum malaria in India.*575 Am J Trop Med Hyg, 2004. **70**(3): p. 256-9.
- 576 14. Menard, D. and A. Dondorp, *Antimalarial Drug Resistance: A Threat to Malaria*577 *Elimination.* Cold Spring Harb Perspect Med, 2017.
- 578 15. Cowman, A.F., et al., Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A, 1988. 85(23): p. 9109-13.
- 581 16. Sirawaraporn, W., et al., Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci U S A, 1997. 94(4): p. 1124-9.
- Triglia, T., et al., Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria.
 EMBO J, 1998. 17(14): p. 3807-15.
- Brooks, D.R., et al., Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem, 1994. 224(2): p. 397-405.
- 590 19. Straimer, J., et al., Drug resistance. K13-propeller mutations confer artemisinin
 591 resistance in Plasmodium falciparum clinical isolates. Science, 2015. 347(6220): p. 428592 31.
- 593 20. Ariey, F., et al., A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature, 2014. 505(7481): p. 50-5.
- 595 21. Dondorp, A.M., et al., *Artemisinin resistance in Plasmodium falciparum malaria*. N Engl
 596 J Med, 2009. 361(5): p. 455-67.
- 597 22. Menard, D., et al., A Worldwide Map of Plasmodium falciparum K13-Propeller
 598 Polymorphisms. N Engl J Med, 2016. 374(25): p. 2453-64.
- 599 23. Miotto, O., et al., *Genetic architecture of artemisinin-resistant Plasmodium falciparum*.
 600 Nat Genet, 2015. 47(3): p. 226-34.
- Sisowath, C., et al., *In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.* J Infect Dis, 2009. **199**(5): p. 750-7.
- Sisowath, C., et al., *In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)*. J Infect Dis, 2005. **191**(6): p. 1014-7.
- 606 26. Dokomajilar, C., et al., Selection of Plasmodium falciparum pfmdr1 alleles following
 607 therapy with artemether-lumefantrine in an area of Uganda where malaria is highly
 608 endemic. Antimicrob Agents Chemother, 2006. 50(5): p. 1893-5.
- Humphreys, G.S., et al., Amodiaquine and artemether-lumefantrine select distinct alleles
 of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for
 uncomplicated malaria. Antimicrob Agents Chemother, 2007. 51(3): p. 991-7.

- 612 28. Sehgal, P.N.S., M. I. D.; Sharma, S. L.; Gogai, S., *Resistance to chloroquine in falciparum malaria in Assam State, India.* Journal of Communicable Diseases, 1973.
 614 5(4): p. 175–180.
- 615 29. Saliba, K.J., P.I. Folb, and P.J. Smith, *Role for the plasmodium falciparum digestive vacuole in chloroquine resistance*. Biochem Pharmacol, 1998. 56(3): p. 313-20.
- 617 30. Mehlotra, R.K., et al., Evolution of a unique Plasmodium falciparum chloroquine618 resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and
 619 South America. Proc Natl Acad Sci U S A, 2001. 98(22): p. 12689-94.
- Mixson-Hayden, T., et al., *Evidence of selective sweeps in genes conferring resistance to chloroquine and pyrimethamine in Plasmodium falciparum isolates in India*. Antimicrob
 Agents Chemother, 2010. 54(3): p. 997-1006.
- 32. Mallick, P.K., et al., *Microsatellite analysis of chloroquine resistance associated alleles and neutral loci reveal genetic structure of Indian Plasmodium falciparum*. Infect Genet
 Evol, 2013. 19: p. 164-75.
- Sutar, S.K., et al., Sequence analysis of coding DNA fragments of pfcrt and pfmdr-1 *genes in Plasmodium falciparum isolates from Odisha, India.* Mem Inst Oswaldo Cruz,
 2011. 106(1): p. 78-84.
- 629 34. Kar, N.P., et al., Comparative assessment on the prevalence of mutations in the
 630 Plasmodium falciparum drug-resistant genes in two different ecotypes of Odisha state,
 631 India. Infect Genet Evol, 2016. 41: p. 47-55.
- 632 35. Sa, J.M., et al., *Geographic patterns of Plasmodium falciparum drug resistance*633 *distinguished by differential responses to amodiaquine and chloroquine*. Proc Natl Acad
 634 Sci U S A, 2009. 106(45): p. 18883-9.
- 635 36. Veiga, M.I., et al., Globally prevalent PfMDR1 mutations modulate Plasmodium
 636 falciparum susceptibility to artemisinin-based combination therapies. Nat Commun,
 637 2016. 7: p. 11553.
- 638 37. Ahmed, A., et al., *Plasmodium falciparum isolates in India exhibit a progressive increase*639 *in mutations associated with sulfadoxine-pyrimethamine resistance*. Antimicrob Agents
 640 Chemother, 2004. 48(3): p. 879-89.
- 641 38. Tun, K.M., et al., Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a
 642 cross-sectional survey of the K13 molecular marker. Lancet Infect Dis, 2015. 15(4): p.
 643 415-21.
- Saha, P., et al., Comparative efficacies of artemisinin combination therapies in *Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India.* Antimicrob Agents Chemother,
 2012. 56(5): p. 2511-7.
- Mishra, N., et al., Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malar J, 2014. 13: p. 284.
- Mishra, N., et al., Surveillance of artemisinin resistance in Plasmodium falciparum in India using the kelch13 molecular marker. Antimicrob Agents Chemother, 2015. 59(5):
 p. 2548-53.
- 42. Mishra, N., et al., *Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern region of India*. Malar J, 2016. **15**(1): p. 583.
- 655 43. Chatterjee, M., et al., *No Polymorphism in Plasmodium falciparum K13 Propeller Gene*656 *in Clinical Isolates from Kolkata, India.* J Pathog, 2015. 2015: p. 374354.

- 44. Talundzic, E., et al., Molecular Epidemiology of Plasmodium falciparum kelch13
 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing.
 Antimicrob Agents Chemother, 2017. 61(3).
- 45. Mohon, A.N., et al., *Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009-2013)*. Malar J, 2014. 13: p. 431.
- 46. Torrentino-Madamet, M., et al., *Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013.* Malar J, 2014. 13: p. 472.
- 47. Wang, Z., et al., *Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012*. Malar J, 2015. 14: p. 168.
- 48. Rahman, R., et al., Continued Sensitivity of Plasmodium falciparum to Artemisinin in *Guyana, With Absence of Kelch Propeller Domain Mutant Alleles.* Open Forum Infect
 Dis, 2016. 3(3): p. ofw185.
- 49. Mideo, N., et al., *Ahead of the curve: next generation estimators of drug resistance in malaria infections.* Trends Parasitol, 2013. 29(7): p. 321-8.
- 671